Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123.

This multicenter real-world study from Brazil and Argentina assessed the KEYNOTE-522 neoadjuvant chemo-immunotherapy reg...

Continue ReadingNeoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123.